Biological Products, (No Diagnostic Substances) · DE · CIK 1820190
Scilex acquires, develops, and commercializes non-opioid pain management products, including ZTlido, ELYXYB, and GLOPERBA
Comparable business profile · signals at a glance
In the 90 days to Dec 30, 2025: 1 sold $12.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 30, 2025 | Scilex Holding CoTenPercentOwner | Sell | 9,657,300 | $0.54 | $5.2M |
| Dec 29, 2025 | Scilex Holding CoTenPercentOwner | Sell | 7,310,984 | $0.66 | $4.8M |
| Dec 26, 2025 | Scilex Holding CoTenPercentOwner | Sell | 3,689,016 | $0.75 | $2.8M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.